EX-99.2O 3 a2019q2exhibit992o.htm EXHIBIT 99.2O Exhibit

Exhibit 99.2O


Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
SECOND QUARTER
 
 
 
 
 
Percent Change
 
2019
 
2018
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
geographic area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
 $ 10,403
 
  10,640
 
  (2.2)
%
          (2.2)
 
—

 
 
 
 
 
 
 
 
 
 
Europe
      4,733
 
    4,810
 
(1.6)
 
            4.7
 
        (6.3)

Western Hemisphere excluding U.S.
      1,455
 
    1,540
 
  (5.5)
 
            4.2
 
        (9.7)

Asia-Pacific, Africa
      3,971
 
    3,840
 
   3.4
 
            7.2
 
        (3.8)

International
    10,159
 
  10,190
 
  (0.3)
 
            5.5
 
        (5.8)

 
 
 
  
 
  
 
  
 
  
Worldwide
 $ 20,562
 
  20,830
 
  (1.3)
%
            1.6
 
        (2.9)

 
 
 
 
 
 
 
 
 
 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.





Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
SIX MONTHS
 
 
 
 
 
Percent Change
 
2019
 
2018
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
geographic area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
 $ 20,532
 
  20,591
 
  (0.3)
%
          (0.3)
 
—

 
 
 
 
 
 
 
 
 
 
Europe
      9,342
 
    9,607
 
  (2.8)
 
            4.6
 
        (7.4)

Western Hemisphere excluding U.S.
      2,958
 
    3,107
 
  (4.8)
 
            6.5
 
      (11.3)

Asia-Pacific, Africa
      7,751
 
    7,534
 
   2.9
 
            7.0
 
        (4.1)

International
    20,051
 
  20,248
 
  (1.0)
 
            5.8
 
        (6.8)

 
 
 
  
 
  
 
  
 
  
Worldwide
 $ 40,583
 
  40,839
 
  (0.6)
%
            2.7
 
        (3.3)

 
 
 
 
 
 
 
 
 
 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
SECOND QUARTER
 
 
 
 
 
Percent Change
 
2019
 
2018
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
segment of business
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
 
 
 
    U.S.
 $ 1,537
 
    1,476
 
   4.1
%
            4.1
 
—

    International
      2,007
 
    2,028
 
  (1.0)
 
            4.9
 
        (5.9)

 
      3,544
   
    3,504
 
   1.2
 
            4.6
 
        (3.4)

 
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
    U.S.
      5,783
 
    5,899
 
  (2.0)
 
          (2.0)
 
—

    International
      4,746
 
    4,455
 
   6.5
 
          12.9
 
        (6.4)

 
    10,529
   
  10,354
 
   1.7
 
            4.4
 
        (2.7)

 
 
 
 
 
 
 
 
 
 
Medical Devices
 
 
 
 
 
 
 
 
 
    U.S.
      3,083
   
    3,265
 
  (5.6)
 
          (5.6)
 
—

    International
      3,406
 
    3,707
 
  (8.1)
 
          (2.9)
 
        (5.2)

 
      6,489
   
    6,972
 
  (6.9)
 
          (4.1)
 
        (2.8)

 
 
 
 
 
 
 
 
 
 
U.S.
    10,403
 
  10,640
 
  (2.2)
 
          (2.2)
 
—

International
    10,159
 
  10,190
 
  (0.3)
 
            5.5
 
        (5.8)

Worldwide
 $ 20,562
 
  20,830
 
  (1.3)
%
            1.6
 
        (2.9)

 
 
 
 
 
 
 
 
 
 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.





























Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
SIX MONTHS
 
 
 
 
 
Percent Change
 
2019
 
2018
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
segment of business
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
 
 
 
    U.S.
 $ 2,975
 
    2,912
 
   2.2
%
            2.2
 
—

    International
      3,887
 
    3,990
 
  (2.6)
 
            4.3
 
        (6.9)

 
      6,862
   
    6,902
 
  (0.6)
 
            3.4
 
        (4.0)

 
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
    U.S.
    11,365
 
  11,253
 
   1.0
 
            1.0
 
—

    International
      9,408
 
    8,945
 
   5.2
 
          12.5
 
        (7.3)

 
    20,773
   
  20,198
 
   2.8
 
            6.1
 
        (3.3)

 
 
 
 
 
 
 
 
 
 
Medical Devices
 
 
 
 
 
 
 
 
 
    U.S.
      6,192
   
    6,426
 
  (3.6)
 
          (3.6)
 
—

    International
      6,756
 
    7,313
 
  (7.6)
 
          (1.6)
 
        (6.0)

 
    12,948
   
  13,739
 
  (5.7)
 
          (2.6)
 
        (3.1)

 
 
 
 
 
 
 
 
 
 
U.S.
    20,532
 
  20,591
 
  (0.3)
 
          (0.3)
 
—

International
    20,051
 
  20,248
 
  (1.0)
 
            5.8
 
        (6.8)

Worldwide
 $ 40,583
 
  40,839
 
  (0.6)
%
            2.7
 
        (3.3)

 
 
 
 
 
 
 
 
 
 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.




Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Condensed Consolidated Statement of Earnings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
SECOND QUARTER
 
 
 
 
 
 
 
 
 
 
 
2019
 
2018
 
Percent
 
 
 
Percent
 
 
 
Percent
 
Increase
 
Amount
 
to Sales
 
Amount
 
to Sales
 
(Decrease)
Sales to customers
 $ 20,562
 
         100.0
 
 $ 20,830
 
         100.0
 
(1.3)
Cost of products sold
         6,940
 
           33.8
 
         6,927
 
           33.3
 
0.2
Gross Profit
       13,622
 
           66.2
 
       13,903
 
           66.7
 
(2.0)
Selling, marketing and administrative expenses
         5,546
 
           27.0
 
         5,743
 
           27.5
 
(3.4)
Research and development expense
         2,666
 
           13.0
 
         2,639
 
           12.7
 
1.0
Interest (income) expense, net
               (5)
 
             0.0
 
            127
 
             0.6
 
 
Other (income) expense, net
        (1,683)
 
            (8.2)
 
            364
 
             1.7
 
 
Restructuring
              57
 
             0.2
 
              57
 
             0.3
 
 
Earnings before provision for taxes on income
         7,041
 
           34.2
 
         4,973
 
           23.9
 
41.6
Provision for taxes on income
         1,434
 
             6.9
 
         1,019
 
             4.9
 
40.7
Net earnings
 $ 5,607
 
           27.3
 
 $ 3,954
 
           19.0
 
41.8
 
 
 
 
 
 
 
 
 
 
Net earnings per share (Diluted)
 $ 2.08
 
 
 
 $ 1.45
 
 
 
43.4
 
 
 
 
 
 
 
 
 
 
Average shares outstanding (Diluted)
2,691.7
 
 
 
2,721.3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
20.4
%
 
 
20.5
%
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted earnings before provision for taxes and net earnings (1) (A)
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income
 $ 8,614
 
41.9
 
 $ 7,014
 
33.7
 
22.8
Net earnings
 $ 6,950
 
33.8
 
 $ 5,718
 
27.5
 
21.5
Net earnings per share (Diluted)
 $ 2.58
 
 
 
 $ 2.10
 
 
 
22.9
Effective tax rate
19.3
%
 
 
18.5
%
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) See Reconciliation of Non-GAAP Financial Measures.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.














Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Condensed Consolidated Statement of Earnings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
SIX MONTHS
 
 
 
 
 
 
 
 
 
 
 
2019
 
2018
 
Percent
 
 
 
Percent
 
 
 
Percent
 
Increase
 
Amount
 
to Sales
 
Amount
 
to Sales
 
(Decrease)
Sales to customers
 $ 40,583
 
         100.0
 
 $ 40,839

 
         100.0

 
(0.6)
Cost of products sold
       13,555
 
           33.4
 
       13,541

 
           33.2

 
0.1
Gross Profit
       27,028
 
           66.6
 
       27,298

 
           66.8

 
(1.0)
Selling, marketing and administrative expenses
       10,765
 
           26.5
 
       11,006

 
           27.0

 
(2.2)
Research and development expense
         5,524
 
           13.6
 
         5,043

 
           12.3

 
9.5
In-process research and development
            890
 
             2.2
 
—

 
—

 
 
Interest (income) expense, net
               (2)
 
             0.0
 
            272

 
             0.7

 
 
Other (income) expense, net
        (1,705)
 
            (4.2)
 
            424

 
             1.0

 
 
Restructuring
              93
 
             0.3
 
              99

 
             0.2

 
 
Earnings before provision for taxes on income
       11,463
 
           28.2
 
       10,454

 
           25.6

 
9.7
Provision for taxes on income
         2,107
 
             5.1
 
         2,133

 
             5.2

 
(1.2)
Net earnings
 $ 9,356
 
           23.1
 
 $ 8,321

 
           20.4

 
12.4
 
 
 
 
 
 
 
 
 
 
Net earnings per share (Diluted)
 $ 3.47
 
 
 
 $ 3.05

 
 
 
13.8
 
 
 
 
 
 
 
 
 
 
Average shares outstanding (Diluted)
2,697.0
 
 
 
2,728.5

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
18.4
%
 
 
20.4

%
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted earnings before provision for taxes and net earnings (1) (A)
 
 
 
 
 
 
 
Earnings before provision for taxes on income
 $ 15,481
 
38.1
 
 $ 13,872

 
34.0

 
11.6
Net earnings
 $ 12,611
 
31.1
 
 $ 11,353

 
27.8

 
11.1
Net earnings per share (Diluted)
 $ 4.68
 
 
 
 $ 4.16

 
 
 
12.5
Effective tax rate
18.5
%
 
 
18.2

%
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) See Reconciliation of Non-GAAP Financial Measures.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measures
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Second Quarter
 
% Incr. /
 
 
 
 
(Dollars in Millions Except Per Share Data)
 
 
2019
 
2018
 
(Decr.)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income - as reported
 
 
 $ 7,041

 
         4,973

 
           41.6
%
 
 
 
Intangible asset amortization expense
 
 
         1,118

 
         1,084

 
 
 
 
 
 
In-process research and development
 
 
—

 
—

 
 
 
 
 
 
Litigation expense, net
 
 
            409

 
            703

 
 
 
 
 
 
Restructuring/Other (1)
 
 
            142

 
            176

 
 
 
 
 
 
Actelion acquisition related cost
 
 
              51

 
              64

 
 
 
 
 
 
AMO acquisition related cost
 
 
              13

 
              25

 
 
 
 
 
 
Auris Health acquisition related
 
 
               (9)

 
—

 
 
 
 
 
 
Unrealized loss/(gain) on securities
 
 
           (148)

 
             (39)

 
 
 
 
 
 
Diabetes asset impairment
 
 
—

 
                4

 
 
 
 
 
 
Other
 
 
               (3)

 
              24

 
 
 
 
 
 
Earnings before provision for taxes on income - as adjusted
 
 
 $ 8,614

 
         7,014

 
           22.8
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net Earnings - as reported
 
 
 $ 5,607

 
         3,954

 
           41.8
%
 
 
 
Intangible asset amortization expense
 
 
            979

 
            967

 
 
 
 
 
 
In-process research and development
 
 
—

 
—

 
 
 
 
 
 
Litigation expense, net
 
 
            342

   
            609

   
 
 
 
 
 
Restructuring/Other
 
 
            116

 
            152

 
 
 
 
 
 
Actelion acquisition related cost
 
 
              47

 
              64

 
 
 
 
 
 
AMO acquisition related cost
 
 
              10

 
              22

 
 
 
 
 
 
Auris Health acquisition related
 
 
               (7)

 
—

 
 
 
 
 
 
Unrealized loss/(gain) on securities
 
 
           (117)

 
             (31)

 
 
 
 
 
 
Diabetes asset impairment
 
 
—

 
                3

 
 
 
 
 
 
Impact of tax legislation (2)
 
 
—

 
             (40)

 
 
 
 
 
 
Other
 
 
             (27)

 
              18

 
 
 
 
 
 
Net Earnings - as adjusted
 
 
 $ 6,950

 
         5,718

 
           21.5
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diluted Net Earnings per share - as reported
 
 
 $ 2.08

 
           1.45

 
           43.4
%
 
 
 
Intangible asset amortization expense
 
 
           0.36

 
           0.36

 
 
 
 
 
 
In-process research and development
 
 
—

 
—

 
 
 
 
 
 
Litigation expense, net
 
 
           0.13

 
           0.22

 
 
 
 
 
 
Restructuring/Other
 
 
           0.04

 
           0.06

 
 
 
 
 
 
Actelion acquisition related cost
 
 
           0.02

 
           0.02

 
 
 
 
 
 
AMO acquisition related cost
 
 
—

 
           0.01

 
 
 
 
 
 
Auris Health acquisition related
 
 
—

 
—

 
 
 
 
 
 
Unrealized loss/(gain) on securities
 
 
          (0.04)

 
          (0.01)

 
 
 
 
 
 
Diabetes asset impairment
 
 
—

 
—

 
 
 
 
 
 
Impact of tax legislation
 
 
—

 
          (0.02)

 
 
 
 
 
 
Other
 
 
          (0.01)

 
           0.01

 
 
 
 
 
 
Diluted Net Earnings per share - as adjusted
 
 
 $ 2.58

 
           2.10

 
           22.9
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Operational Diluted Net Earnings per share - as adjusted
 
 
 
 
 
 
 
 
 
 
 
at 2017 foreign currency exchange rates
 
 
 
 
           2.04

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impact of currency at 2018 foreign currency exchange rates
 
 
           0.05

 
           0.06

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Operational Diluted Net Earnings per share - as adjusted
 
 
 
 
 
 
 
 
 
 
 
at 2018 foreign currency exchange rates
 
 
 $ 2.63

 
           2.10

 
           25.2
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Includes $38M recorded in cost of products sold and $47M recorded in other (income) expense for the second quarter 2019. Includes $44M recorded in cost of products sold and $75M recorded in other (income) expense for the second quarter 2018.

 
 
 
 
 
 
 
 
 
 
 
 
(2) Includes foreign currency translation
 
 
 
 
 
 
 
 
 
 
 





Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measures
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Six Months YTD
 
% Incr. /
 
 
 
 
(Dollars in Millions Except Per Share Data)
 
 
2019
 
2018
 
(Decr.)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income - as reported
 
 
 $ 11,463

 
       10,454

 
             9.7
%
 
 
 
Intangible asset amortization expense
 
 
         2,248

 
         2,199

 
 
 
 
 
 
In-process research and development
 
 
            890

 
—

 
 
 
 
 
 
Litigation expense, net
 
 
            832

 
            703

 
 
 
 
 
 
Restructuring/Other (1)
 
 
            232

 
            283

 
 
 
 
 
 
Actelion acquisition related cost
 
 
              90

 
            160

 
 
 
 
 
 
AMO acquisition related cost
 
 
              41

 
              46

 
 
 
 
 
 
Auris Health acquisition related
 
 
(9
)
 
—

 
 
 
 
 
 
Unrealized loss/(gain) on securities
 
 
(306
)
 
             (12)

 
 
 
 
 
 
Diabetes asset impairment
 
 
—

 
                4

 
 
 
 
 
 
Other
 
 
—

 
              35

 
 
 
 
 
 
Earnings before provision for taxes on income - as adjusted
 
 
 $ 15,481

 
       13,872

 
           11.6
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net Earnings - as reported
 
 
 $ 9,356

 
         8,321

 
           12.4
%
 
 
 
Intangible asset amortization expense
 
 
         1,825

 
         1,963

 
 
 
 
 
 
In-process research and development
 
 
            703

 
—

 
 
 
 
 
 
Litigation expense, net
 
 
            684

 
            609

 
 
 
 
 
 
Restructuring/Other
 
 
            191

 
            233

 
 
 
 
 
 
Actelion acquisition related cost
 
 
              84

 
            156

 
 
 
 
 
 
AMO acquisition related cost
 
 
              33

 
              39

 
 
 
 
 
 
Auris Health acquisition related
 
 
(7
)
 
—

 
 
 
 
 
 
Unrealized loss/(gain) on securities
 
 
(242
)
 
             (10)

 
 
 
 
 
 
Diabetes asset impairment
 
 
—

 
                3

 
 
 
 
 
 
Impact of tax legislation (2)
 
 
—

 
              12

 
 
 
 
 
 
Other
 
 
(16
)
 
              27

 
 
 
 
 
 
Net Earnings - as adjusted
 
 
 $ 12,611

 
       11,353

 
           11.1
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diluted Net Earnings per share - as reported
 
 
 $ 3.47

 
           3.05

 
           13.8
%
 
 
 
Intangible asset amortization expense
 
 
           0.68

 
           0.72

 
 
 
 
 
 
In-process research and development
 
 
           0.26

 
—

 
 
 
 
 
 
Litigation expense, net
 
 
           0.26

 
           0.22

 
 
 
 
 
 
Restructuring/Other
 
 
           0.07

 
           0.09

 
 
 
 
 
 
Actelion acquisition related cost
 
 
           0.03

 
           0.05

 
 
 
 
 
 
AMO acquisition related cost
 
 
           0.01

 
           0.01

 
 
 
 
 
 
Auris Health acquisition related
 
 
—

 
—

 
 
 
 
 
 
Unrealized loss/(gain) on securities
 
 
(0.09
)
 
—

 
 
 
 
 
 
Diabetes asset impairment
 
 
—

 
—

 
 
 
 
 
 
Impact of tax legislation
 
 
—

 
           0.01

 
 
 
 
 
 
Other
 
 
(0.01
)
 
           0.01

 
 
 
 
 
 
Diluted Net Earnings per share - as adjusted
 
 
 $ 4.68

 
           4.16

 
           12.5
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Operational Diluted Net Earnings per share - as adjusted
 
 
 
 
 
 
 
 
 
 
 
at 2017 foreign currency exchange rates
 
 
 
 
           3.97

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impact of currency at 2018 foreign currency exchange rates
 
 
           0.13

 
           0.19

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Operational Diluted Net Earnings per share - as adjusted
 
 
 
 
 
 
 
 
 
 
 
at 2018 foreign currency exchange rates
 
 
 $ 4.81

 
           4.16

 
           15.6
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Includes $61M recorded in cost of products sold and $78M recorded in other (income) expense for six months 2019 YTD. Includes $50M recorded in cost of products sold and $134M recorded in other (income) expense for six months 2018 YTD.

 
 
 
 
 
 
 
 
 
 
 
 
(2) Includes foreign currency translation
 
 
 
 
 
 
 
 
 
 
 



Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted Operational Sales Growth (A)
 SECOND QUARTER 2019 ACTUAL vs. 2018 ACTUAL
 
 Segments
 
 
 
 
 
 
 
 
 
 
 
 Consumer
 
 Pharmaceutical
 
 Medical Devices
 
 Total
 WW As Reported
 
1.2%
 
1.7%
 
(6.9)%
 
(1.3)%
 U.S.
 
4.1%
 
(2.0)%
 
(5.6)%
 
(2.2)%
 International
 
(1.0)%
 
6.5%
 
(8.1)%
 
(0.3)%
 
 
 
 
 
 
 
 
 
 WW Currency
 
(3.4)
 
(2.7)
 
(2.8)
 
(2.9)
 U.S.
 
—
 
—
 
—
 
—
 International
 
(5.9)
 
(6.4)
 
(5.2)
 
(5.8)
 
 
 
 
 
 
 
 
 
 WW Operational
 
4.6%
 
4.4%
 
(4.1)%
 
1.6%
 U.S.
 
4.1%
 
(2.0)%
 
(5.6)%
 
(2.2)%
 International
 
4.9%
 
12.9%
 
(2.9)%
 
5.5%
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
Nizoral
 
0.6
 
 
 
 
 
0.1
 U.S.
 
0.3
 
 
 
 
 
0.0
 International
 
0.7
 
 
 
 
 
0.1
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
Zarbees
 
(0.6)
 
 
 
 
 
(0.1)
 U.S.
 
(1.4)
 
 
 
 
 
(0.2)
 International
 
0.0
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
Diabetes Care
 
 
 
 
 
 
 
 
LifeScan
 
 
 
 
 
5.1
 
1.7
 U.S.
 
 
 
 
 
4.0
 
1.2
 International
 
 
 
 
 
6.2
 
2.3
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
RoC
 
0.7
 
 
 
 
 
0.1
 U.S.
 
1.3
 
 
 
 
 
0.2
 International
 
0.3
 
 
 
 
 
0.1
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
Dr. Ci Labo - Japan
 
(3.0)
 
 
 
 
 
(0.5)
 U.S.
 
0.0
 
 
 
 
 
0.0
 International
 
(5.2)
 
 
 
 
 
(1.0)
 
 
 
 
 
 
 
 
 
Specialty Surgery
 
 
 
 
 
 
 
 
Advanced Sterilization Products
 
 
 
 
 
2.0
 
0.7
 U.S.
 
 
 
 
 
3.0
 
0.9
 International
 
 
 
 
 
1.2
 
0.5
 
 
 
 
 
 
 
 
 
All Other Acquisitions and Divestitures
 
0.0
 
0.0
 
0.1
 
0.0
 U.S.
 
0.0
 
0.0
 
0.1
 
0.0
 International
 
0.1
 
0.0
 
0.1
 
0.0
 
 
 
 
 
 
 
 
 
WW Adjusted Operational
 
2.3%
 
4.4%
 
3.2%
 
3.7%
 U.S.
 
4.4%
 
(2.0)%
 
1.6%
 
0.0%
 International
 
0.7%
 
12.9%
 
4.7%
 
7.6%
 
 
 
 
 
 
 
 
 
Note: Percentages are based on actual, non-rounded figures and may not sum
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted Operational Sales Growth (A)
 SIX MONTHS 2019 ACTUAL vs. 2018 ACTUAL
 
 
 
 
 
 
 
 
 
 Segments
 
 
 
 
 
 
 
 
 
 
 
 Consumer
 
 Pharmaceutical
 
 Medical Devices
 
 Total
 WW As Reported
 
(0.6)%
 
2.8%
 
(5.7)%
 
(0.6)%
 U.S.
 
2.2%
 
1.0%
 
(3.6)%
 
(0.3)%
 International
 
(2.6)%
 
5.2%
 
(7.6)%
 
(1.0)%
 
 
 
 
 
 
 
 
 
 WW Currency
 
(4.0)
 
(3.3)
 
(3.1)
 
(3.3)
 U.S.
 
—
 
—
 
—
 
—
 International
 
(6.9)
 
(7.3)
 
(6.0)
 
(6.8)
 
 
 
 
 
 
 
 
 
 WW Operational
 
3.4%
 
6.1%
 
(2.6)%
 
2.7%
 U.S.
 
2.2%
 
1.0%
 
(3.6)%
 
(0.3)%
 International
 
4.3%
 
12.5%
 
(1.6)%
 
5.8%
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
Nizoral
 
0.5
 
 
 
 
 
0.1
 U.S.
 
0.3
 
 
 
 
 
0.0
 International
 
0.6
 
 
 
 
 
0.1
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
Zarbees
 
(0.7)
 
 
 
 
 
(0.1)
 U.S.
 
(1.7)
 
 
 
 
 
(0.2)
 International
 
0.0
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
Diabetes Care
 
 
 
 
 
 
 
 
LifeScan
 
 
 
 
 
5.1
 
1.7
 U.S.
 
 
 
 
 
3.9
 
1.2
 International
 
 
 
 
 
6.1
 
2.3
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
RoC
 
0.8
 
 
 
 
 
0.1
 U.S.
 
1.4
 
 
 
 
 
0.2
 International
 
0.3
 
 
 
 
 
0.1
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
Dr. Ci Labo - Japan
 
(2.6)
 
 
 
 
 
(0.4)
 U.S.
 
0.0
 
 
 
 
 
0.0
 International
 
(4.4)
 
 
 
 
 
(0.9)
 
 
 
 
 
 
 
 
 
Specialty Surgery
 
 
 
 
 
 
 
 
Advanced Sterilization Products
 
 
 
 
 
1.1
 
0.4
 U.S.
 
 
 
 
 
1.5
 
0.5
 International
 
 
 
 
 
0.6
 
0.2
 
 
 
 
 
 
 
 
 
All Other Acquisitions and Divestitures
 
0.1
 
0.0
 
0.1
 
0.1
 U.S.
 
0.0
 
0.0
 
0.2
 
0.1
 International
 
0.2
 
0.0
 
0.1
 
0.1
 
 
 
 
 
 
 
 
 
WW Adjusted Operational
 
1.5%
 
6.1%
 
3.8%
 
4.6%
 U.S.
 
2.2%
 
1.0%
 
2.1%
 
1.5%
 International
 
1.0%
 
12.5%
 
5.3%
 
7.7%
 
 
 
 
 
 
 
 
 
Note: Percentages are based on actual, non-rounded figures and may not sum
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.





Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
SECOND QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

CONSUMER SEGMENT (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BABY CARE
 
 
 
 
 
 
 
 
 
US
 
$
99

 
89

 
11.5
 %
11.5
 %
—
 %
Intl
 
 
344

 
367

 
(6.3
)
0.0

(6.3
)
WW
 
 
443

 
456

 
(2.8
)
2.2

(5.0
)
 
 
 
 
 
 
 
 
 
 
BEAUTY
 
 
 
 
 
 
 
 
 
US
 
 
663

 
637

 
4.1

4.1

—

Intl
 
 
539

 
472

 
14.1

19.5

(5.4
)
WW
 
 
1,202

 
1,109

 
8.4

10.7

(2.3
)
 
 
 
 
 
 
 
 
 
 
ORAL CARE
 
 
 
 
 
 
 
 
 
US
 
 
155

 
157

 
(1.6
)
(1.6
)
—

Intl
 
 
234

 
236

 
(0.7
)
5.3

(6.0
)
WW
 
 
389

 
393

 
(1.1
)
2.5

(3.6
)
 
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
 
US
 
 
484

 
454

 
6.6

6.6

—

Intl
 
 
580

 
612

 
(5.1
)
0.0

(5.1
)
WW
 
 
1,064

 
1,066

 
(0.1
)
2.8

(2.9
)
 
 
 
 
 
 
 
 
 
 
WOMEN'S HEALTH
 
 
 
 
 
 
 
 
 
US
 
 
3

 
4

 
(10.3
)
(10.3
)
—

Intl
 
 
250

 
276

 
(9.5
)
(1.3
)
(8.2
)
WW
 
 
253

 
280

 
(9.5
)
(1.4
)
(8.1
)
 
 
 
 
 
 
 
 
 
 
WOUND CARE / OTHER
 
 
 
 
 
 
 
 
 
US
 
 
132

 
135

 
(1.9
)
(1.9
)
—

Intl
 
 
61

 
65

 
(6.4
)
(2.0
)
(4.4
)
WW
 
 
193

 
200

 
(3.4
)
(1.9
)
(1.5
)
 
 
 
 
 
 
 
 
 
 
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
US
 
 
1,537

 
1,476

 
4.1

4.1

—

Intl
 
 
2,007

 
2,028

 
(1.0
)
4.9

(5.9
)
WW
 
$
3,544

 
3,504

 
1.2
 %
4.6
 %
(3.4
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 





Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
SECOND QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (4)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMMUNOLOGY
 
 
 
 
 
 
 
 
 
US
 
$
2,379

 
2,317

 
2.7
 %
2.7
 %
—
 %
Intl
 
 
1,087

 
1,021

 
6.3

12.5

(6.2
)
WW
 
 
3,466

 
3,338

 
3.8

5.7

(1.9
)
     REMICADE
 
 
 
 
 
 
 
 
 
     US
 
 
801

 
918
 
(12.7
)
(12.7
)
—

     US Exports (3)
 
 
62

 
104

 
(40.3
)
(40.3
)
—

     Intl
 
 
244

 
298

 
(18.5
)
(13.5
)
(5.0
)
     WW
 
 
1,107

 
1,320

 
(16.2
)
(15.1
)
(1.1
)
     SIMPONI / SIMPONI ARIA
 
 
 
 
 
 
 
 
 
     US
 
 
281

 
274

 
2.7

2.7

—

     Intl
 
 
282

 
274

 
2.7

8.5

(5.8
)
     WW
 
 
563

 
548

 
2.7

5.6

(2.9
)
     STELARA
 
 
 
 
 
 
 
 
 
     US
 
 
1,058

 
919

 
15.2

15.2

—

     Intl
 
 
499

 
422

 
18.1

25.0

(6.9
)
     WW
 
 
1,558

 
1,341

 
16.1

18.3

(2.2
)
     TREMFYA
 
 
 
 
 
 
 
 
 
     US
 
 
176

 
102

 
72.3

72.3

—

     Intl
 
 
59

 
24

 
*

*

*

     WW
 
 
235

 
126

 
86.5

88.9

(2.4
)
     OTHER IMMUNOLOGY (4)
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
3

 
3

 
27.7

27.0

0.7

     WW
 
 
3

 
3

 
27.7

27.0

0.7

 
 
 
 
 
 
 
 
 
 
INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
US
 
 
387

 
328

 
17.8

17.8

—

Intl
 
 
475

 
521

 
(8.7
)
(2.5
)
(6.2
)
WW
 
 
862

 
849

 
1.5

5.4

(3.9
)
     EDURANT / rilpivirine
 
 
 
 
 
 
 
 
 
     US
 
 
12

 
15

 
(15.8
)
(15.8
)
—

     Intl
 
 
198

 
196

 
0.5

6.6

(6.1
)
     WW
 
 
210

 
211

 
(0.6
)
5.0

(5.6
)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
 
 
 
 
 
 
     US
 
 
344

 
277

 
24.2

24.2

—

     Intl
 
 
191

 
215

 
(11.1
)
(4.6
)
(6.5
)
     WW
 
 
535

 
492

 
8.7

11.6

(2.9
)
     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
     US
 
 
31

 
36

 
(16.6
)
(16.6
)
—

     Intl
 
 
86

 
110

 
(20.8
)
(14.6
)
(6.2
)
     WW
 
 
117

 
146

 
(19.7
)
(15.1
)
(4.6
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
SECOND QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEUROSCIENCE
 
 
 
 
 
 
 
 
 
US
 
$
664

 
639

 
3.8
 %
3.8
 %
—
 %
Intl
 
 
875

 
889

 
(1.6
)
3.9

(5.5
)
WW
 
 
1,538

 
1,528

 
0.6

3.9

(3.3
)
     CONCERTA / methylphenidate
 
 
 
 
 
 
 
 
 
     US
 
 
15

 
68

 
(78.6
)
(78.6
)
—

     Intl
 
 
123

 
115

 
6.2

12.1

(5.9
)
     WW
 
 
137

 
183

 
(25.2
)
(21.5
)
(3.7
)
     INVEGA SUSTENNA / XEPLION / INVEGA
 
 
 
 
 
     TRINZA / TREVICTA
 
 
 
 
 
 
 
 
 
     US
 
 
506

 
438

 
15.6

15.6

—

     Intl
 
 
312

 
282

 
10.4

17.2

(6.8
)
     WW
 
 
818

 
720

 
13.6

16.3

(2.7
)
     RISPERDAL CONSTA
 
 
 
 
 
 
 
 
 
     US
 
 
81

 
80

 
0.8

0.8

—

     Intl
 
 
101

 
108

 
(6.5
)
(0.1
)
(6.4
)
     WW
 
 
182

 
188

 
(3.4
)
0.3

(3.7
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
     US
 
 
62

 
53

 
16.1

16.1

—

     Intl
 
 
340

 
384

 
(11.5
)
(7.3
)
(4.2
)
     WW
 
 
401

 
437

 
(8.1
)
(4.4
)
(3.7
)
 
 
 
 
 
 
 
 
 
 
ONCOLOGY
 
 
 
 
 
 
 
 
 
US
 
 
1,013

 
1,085

 
(6.6
)
(6.6
)
—

Intl
 
 
1,684

 
1,371

 
22.8

30.5

(7.7
)
WW
 
 
2,697

 
2,456

 
9.8

14.1

(4.3
)
     DARZALEX
 
 
 
 
 
 
 
 
 
     US
 
 
369

 
298

 
24.4

24.4

—

     Intl
 
 
405

 
213

 
89.5

*

(13.6
)
     WW
 
 
774

 
511

 
51.6

57.3

(5.7
)
     IMBRUVICA
 
 
 
 
 
 
 
 
 
     US
 
 
367

 
250

 
47.0

47.0

—

     Intl
 
 
463

 
370

 
25.3

33.9

(8.6
)
     WW
 
 
831

 
620

 
34.1

39.2

(5.1
)
     VELCADE
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
224

 
280

 
(20.1
)
(16.1
)
(4.0
)
     WW
 
 
224

 
280

 
(20.1
)
(16.1
)
(4.0
)
     ZYTIGA / abiraterone acetate
 
 
 
 
 
 
 
 
 
     US
 
 
198

 
486

 
(59.4
)
(59.4
)
—

     Intl
 
 
500

 
423

 
18.0

24.5

(6.5
)
     WW
 
 
698

 
909

 
(23.3
)
(20.3
)
(3.0
)
     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 
78

 
51

 
50.5

50.5

—

     Intl
 
 
92

 
85

 
8.8

16.2

(7.4
)
     WW
 
 
170

 
136

 
24.7

29.3

(4.6
)
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
SECOND QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
PULMONARY HYPERTENSION
 
 
 
 
 
 
US
 
$
439

 
429

 
2.2
 %
2.2
 %
—
 %
Intl
 
 
251

 
236

 
6.7

12.7

(6.0
)
WW
 
 
690

 
665

 
3.8

6.0

(2.2
)
     OPSUMIT
 
 
 
 
 
 
 
 
 
     US
 
 
203

 
180

 
12.8

12.8

—

     Intl
 
 
146

 
131

 
11.5

18.1

(6.6
)
     WW
 
 
348

 
311

 
12.3

15.0

(2.7
)
     TRACLEER
 
 
 
 
 
 
 
 
 
     US
 
 
41

 
71

 
(41.8
)
(41.8
)
—

     Intl
 
 
62

 
72

 
(14.5
)
(10.9
)
(3.6
)
     WW
 
 
103

 
143

 
(28.0
)
(26.2
)
(1.8
)
     UPTRAVI
 
 
 
 
 
 
 
 
 
     US
 
 
175

 
155

 
13.4

13.4

—

     Intl
 
 
28

 
16

 
62.5

71.6

(9.1
)
     WW
 
 
203

 
171

 
18.2

19.1

(0.9
)
     OTHER
 
 
 
 
 
 
 
     US
 
 
20

 
23

 
(18.2
)
(18.2
)
—

     Intl
 
 
16

 
17

 
3.7

13.3

(9.6
)
     WW
 
 
37

 
40

 
(9.6
)
(5.8
)
(3.8
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
SECOND QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
CARDIOVASCULAR / METABOLISM / OTHER
 
 
 
 
 
 
US
 
$
902

 
1,101

 
(18.1
)%
(18.1
)%
—
 %
Intl
 
 
373

 
417

 
(10.5
)
(5.7
)
(4.8
)
WW
 
 
1,275

 
1,518

 
(16.0
)
(14.7
)
(1.3
)
     XARELTO
 
 
 
 
 
 
 
 
 
     US
 
 
549

 
679

 
(19.2
)
(19.2
)
—

     Intl
 
 
—

 
—

 
—

—

—

     WW
 
 
549

 
679

 
(19.2
)
(19.2
)
—

     INVOKANA / INVOKAMET
 
 
 
 
 
 
 
 
 
     US
 
 
132

 
169

 
(21.2
)
(21.2
)
—

     Intl
 
 
43

 
46

 
(6.0
)
(1.5
)
(4.5
)
     WW
 
 
177

 
215

 
(17.9
)
(16.9
)
(1.0
)
     PROCRIT / EPREX
 
 
 
 
 
 
 
 
 
     US
 
 
113

 
156

 
(27.5
)
(27.5
)
—

     Intl
 
 
70

 
80

 
(13.4
)
(9.6
)
(3.8
)
     WW
 
 
183

 
236

 
(22.7
)
(21.4
)
(1.3
)
     OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
107

 
97

 
9.3

9.3

—

     Intl
 
 
260

 
291

 
(10.5
)
(5.2
)
(5.3
)
     WW
 
 
368

 
388

 
(5.5
)
(1.5
)
(4.0
)
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
US
 
 
5,783

 
5,899

 
(2.0
)
(2.0
)
—

Intl
 
 
4,746

 
4,455

 
6.5

12.9

(6.4
)
WW
 
$
10,529

 
10,354

 
1.7
 %
4.4
 %
(2.7
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
SECOND QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (5)
 
 
 
 
 
 
 
 
 
 
 
 
 
DIABETES CARE (5)
 
 
 
 
 
 
US
 
$
—

 
129

 
*%

*%

—
 %
Intl
 
 
—

 
226

 
*

*

*

WW
 
 
—

 
355

 
*

*

*

 
 
 
 
 
 
 
 
 
 
INTERVENTIONAL SOLUTIONS
 
 
 
 
 
 
 
 
 
US
 
 
366

 
323

 
13.7

13.7

—

Intl
 
 
385

 
344

 
11.6

17.3

(5.7
)
WW
 
 
750

 
667

 
12.6

15.6

(3.0
)
 
 
 
 
 
 
 
 
 
 
ORTHOPAEDICS
 
 
 
 
 
 
 
 
 
US
 
 
1,331

 
1,332

 
(0.1
)
(0.1
)
—

Intl
 
 
894

 
930

 
(3.8
)
1.5

(5.3
)
WW
 
 
2,224

 
2,262

 
(1.6
)
0.6

(2.2
)
 
 
 
 
 
 
 
 
 
 
     HIPS
 
 
 
 
 
 
 
 
 
     US
 
 
216

 
211

 
2.1

2.1

—

     Intl
 
 
147

 
149

 
(0.7
)
5.0

(5.7
)
     WW
 
 
364

 
360

 
0.9

3.3

(2.4
)
 
 
 
 
 
 
 
 
 
 
     KNEES
 
 
 
 
     US
 
 
218

 
229

 
(4.8
)
(4.8
)
—

     Intl
 
 
153

 
153

 
0.4

5.4

(5.0
)
     WW
 
 
372

 
382

 
(2.8
)
(0.7
)
(2.1
)
 
 
 
 
 
 
 
 
 
 
     TRAUMA
 
 
 
 
 
 
 
 
 
     US
 
 
407

 
394

 
3.3

3.3

—

     Intl
 
 
265

 
281

 
(5.9
)
(0.6
)
(5.3
)
     WW
 
 
672

 
675

 
(0.6
)
1.7

(2.3
)
 
 
 
 
 
 
 
 
 
 
     SPINE & OTHER
 
 
     US
 
 
490

 
498

 
(1.5
)
(1.5
)
—

     Intl
 
 
328

 
347

 
(5.3
)
0.0

(5.3
)
     WW
 
 
818

 
845

 
(3.1
)
(0.9
)
(2.2
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 


Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
SECOND QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (5) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
SURGERY
 
 
 
 
 
 
US
 
$
926

 
1,022

 
(9.5
)%
(9.5
)%
—
 %
Intl
 
 
1,427

 
1,493

 
(4.4
)
1.5

(5.9
)
WW
 
 
2,353

 
2,515

 
(6.5
)
(3.0
)
(3.5
)
 
 
 
 
 
 
 
 
 
 
     ADVANCED
 
 
 
 
 
 
 
 
 
     US
 
 
396

 
402

 
(1.7
)
(1.7
)
—

     Intl
 
 
633

 
603

 
5.0

11.2

(6.2
)
     WW
 
 
1,029

 
1,005

 
2.3

6.1

(3.8
)
 
 
 
 
 
 
 
 
 
 
     GENERAL
 
 
 
 
 
 
 
 
 
     US
 
 
443

 
436

 
1.6

1.6

—

     Intl
 
 
674

 
733

 
(7.9
)
(2.4
)
(5.5
)
     WW
 
 
1,119

 
1,169

 
(4.3
)
(0.9
)
(3.4
)
 
 
 
 
 
 
 
 
 
 
     SPECIALTY
 
 
 
 
 
 
 
 
 
     US
 
 
87

 
184

 
(53.1
)
(53.1
)
—

     Intl
 
 
120

 
157

 
(23.7
)
(18.2
)
(5.5
)
     WW
 
 
206

 
341

 
(39.6
)
(37.1
)
(2.5
)
 
 
 
 
 
 
 
 
 
 
VISION
 
 
 
 
US
 
 
461

 
459

 
0.4

0.4

—

Intl
 
 
701

 
714

 
(2.0
)
2.2

(4.2
)
WW
 
 
1,161

 
1,173

 
(1.0
)
1.5

(2.5
)
 
 
 
 
 
 
 
 
 
 
     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
333

 
320

 
3.9

3.9

—

     Intl
 
 
509

 
524

 
(2.9
)
1.5

(4.4
)
     WW
 
 
842

 
844

 
(0.3
)
2.4

(2.7
)
     SURGICAL
 
 
 
 
 
 
 
 
 
     US
 
 
128

 
139

 
(7.7
)
(7.7
)
—

     Intl
 
 
191

 
190

 
0.7

4.2

(3.5
)
     WW
 
 
319

 
329

 
(2.8
)
(0.8
)
(2.0
)
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
US
 
 
3,083

 
3,265

 
(5.6
)
(5.6
)
—

Intl
 
 
3,406

 
3,707

 
(8.1
)
(2.9
)
(5.2
)
WW
 
$
6,489

 
6,972

 
(6.9
)%
(4.1
)%
(2.8
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
SIX MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

CONSUMER SEGMENT (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BABY CARE
 
 
 
 
 
 
 
 
 
US
 
$
186

 
186

 
(0.2
)%
(0.2
)%
—
 %
Intl
 
 
651

 
727

 
(10.5
)
(3.2
)
(7.3
)
WW
 
 
837

 
913

 
(8.4
)
(2.6
)
(5.8
)
 
 
 
 
 
 
 
 
 
 
BEAUTY
 
 
 
 
 
 
 
 
 
US
 
 
1,251

 
1,248

 
0.3

0.3

—

Intl
 
 
1,041

 
945

 
10.1

16.3

(6.2
)
WW
 
 
2,292

 
2,193

 
4.5

7.2

(2.7
)
 
 
 
 
 
 
 
 
 
 
ORAL CARE
 
 
 
 
 
 
 
 
 
US
 
 
306

 
314

 
(2.5
)
(2.5
)
—

Intl
 
 
450

 
458

 
(1.7
)
4.9

(6.6
)
WW
 
 
756

 
772

 
(2.0
)
1.9

(3.9
)
 
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
 
US
 
 
991

 
919

 
7.8

7.8

—

Intl
 
 
1,160

 
1,219

 
(4.9
)
1.4

(6.3
)
WW
 
 
2,151

 
2,138

 
0.6

4.2

(3.6
)
 
 
 
 
 
 
 
 
 
 
WOMEN'S HEALTH
 
 
 
 
 
 
 
 
 
US
 
 
6

 
7

 
(3.7
)
(3.7
)
—

Intl
 
 
472

 
516

 
(8.6
)
1.3

(9.9
)
WW
 
 
478

 
523

 
(8.5
)
1.2

(9.7
)
 
 
 
 
 
 
 
 
 
 
WOUND CARE / OTHER
 
 
 
 
 
 
 
 
 
US
 
 
234

 
238

 
(1.5
)
(1.5
)
—

Intl
 
 
114

 
125

 
(8.9
)
(3.9
)
(5.0
)
WW
 
 
348

 
363

 
(4.0
)
(2.3
)
(1.7
)
 
 
 
 
 
 
 
 
 
 
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
US
 
 
2,975

 
2,912

 
2.2

2.2

—

Intl
 
 
3,887

 
3,990

 
(2.6
)
4.3

(6.9
)
WW
 
$
6,862

 
6,902

 
(0.6
)%
3.4
 %
(4.0
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 





Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
SIX MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (4)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMMUNOLOGY
 
 
 
 
 
 
 
 
 
US
 
$
4,542

 
4,317

 
5.2
 %
5.2
 %
—
 %
Intl
 
 
2,175

 
2,063

 
5.4

12.5

(7.1
)
WW
 
 
6,717

 
6,380

 
5.3

7.6

(2.3
)
     REMICADE
 
 
 
 
 
 
 
 
 
     US
 
 
1,575

 
1,834

 
(14.1
)
(14.1
)
—

     US Exports (3)
 
 
138

 
246

 
(43.9
)
(43.9
)
—

     Intl
 
 
496

 
629

 
(21.2
)
(15.5
)
(5.7
)
     WW
 
 
2,209

 
2,709

 
(18.5
)
(17.1
)
(1.3
)
     SIMPONI / SIMPONI ARIA
 
 
 
 
 
 
 
 
 
     US
 
 
544

 
498

 
9.1

9.1

—

     Intl
 
 
543

 
568

 
(4.4
)
2.2

(6.6
)
     WW
 
 
1,087

 
1,066

 
1.9

5.4

(3.5
)
     STELARA
 
 
 
 
 
 
 
 
 
     US
 
 
1,940

 
1,571

 
23.5

23.5

—

     Intl
 
 
1,022

 
831

 
23.0

31.0

(8.0
)
     WW
 
 
2,963

 
2,402

 
23.3

26.1

(2.8
)
     TREMFYA
 
 
 
 
 
 
 
 
 
     US
 
 
344

 
168

 
*

*

—

     Intl
 
 
108

 
30

 
*

*

*

     WW
 
 
452

 
198

 
*

*

*

     OTHER IMMUNOLOGY (4)
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
6

 
5

 
23.6

24.0

(0.4
)
     WW
 
 
6

 
5

 
23.6

24.0

(0.4
)
 
 
 
 
 
 
 
 
 
 
INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
US
 
 
744

 
661

 
12.5

12.5

—

Intl
 
 
964

 
1,018

 
(5.3
)
2.5

(7.8
)
WW
 
 
1,708

 
1,679

 
1.7

6.5

(4.8
)
     EDURANT / rilpivirine
 
 
 
 
 
 
 
 
 
     US
 
 
24

 
29

 
(17.3
)
(17.3
)
—

     Intl
 
 
397

 
392

 
1.4

8.6

(7.2
)
     WW
 
 
421

 
421

 
0.1

6.8

(6.7
)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
 
 
 
 
 
 
     US
 
 
659

 
550

 
19.9

19.9

—

     Intl
 
 
399

 
420

 
(5.0
)
3.4

(8.4
)
     WW
 
 
1,058

 
970

 
9.1

12.7

(3.6
)
     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
     US
 
 
61

 
82

 
(26.0
)
(26.0
)
—

     Intl
 
 
168

 
206

 
(18.6
)
(10.7
)
(7.9
)
     WW
 
 
229

 
288

 
(20.7
)
(15.1
)
(5.6
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
SIX MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEUROSCIENCE
 
 
 
 
 
 
 
 
 
US
 
$
1,387

 
1,263

 
9.8
 %
9.8
 %
—
 %
Intl
 
 
1,780

 
1,824

 
(2.4
)
4.1

(6.5
)
WW
 
 
3,167

 
3,087

 
2.6

6.4

(3.8
)
     CONCERTA / methylphenidate
 
 
 
 
 
 
 
 
 
     US
 
 
112

 
134

 
(16.4
)
(16.4
)
—

     Intl
 
 
239

 
222

 
7.3

13.9

(6.6
)
     WW
 
 
351

 
356

 
(1.6
)
2.5

(4.1
)
     INVEGA SUSTENNA / XEPLION / INVEGA
 
 
 
 
 
     TRINZA / TREVICTA
 
 
 
 
 
 
 
 
 
     US
 
 
989

 
838

 
18.1

18.1

—

     Intl
 
 
619

 
578

 
7.0

14.7

(7.7
)
     WW
 
 
1,608

 
1,416

 
13.6

16.7

(3.1
)
     RISPERDAL CONSTA
 
 
 
 
 
 
 
 
 
     US
 
 
158

 
162

 
(3.0
)
(3.0
)
—

     Intl
 
 
203

 
222

 
(8.4
)
(1.3
)
(7.1
)
     WW
 
 
361

 
384

 
(6.2
)
(2.0
)
(4.2
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
     US
 
 
128

 
129

 
(0.4
)
(0.4
)
—

     Intl
 
 
719

 
802

 
(10.3
)
(4.8
)
(5.5
)
     WW
 
 
847

 
931

 
(8.9
)
(4.1
)
(4.8
)
 
 
 
 
 
 
 
 
 
 
ONCOLOGY
 
 
 
 
 
 
 
 
 
US
 
 
1,975

 
2,018

 
(2.1
)
(2.1
)
—

Intl
 
 
3,240

 
2,749

 
17.9

26.3

(8.4
)
WW
 
 
5,215

 
4,767

 
9.4

14.3

(4.9
)
     DARZALEX
 
 
 
 
 
 
 
 
 
     US
 
 
721

 
562

 
28.5

28.5

—

     Intl
 
 
682

 
381

 
78.7

93.0

(14.3
)
     WW
 
 
1,403

 
943

 
48.8

54.6

(5.8
)
     IMBRUVICA
 
 
 
 
 
 
 
 
 
     US
 
 
716

 
477

 
50.2

50.2

—

     Intl
 
 
898

 
730

 
23.1

33.0

(9.9
)
     WW
 
 
1,615

 
1,207

 
33.8

39.8

(6.0
)
     VELCADE
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
487

 
593

 
(17.9
)
(12.9
)
(5.0
)
     WW
 
 
487

 
593

 
(17.9
)
(12.9
)
(5.0
)
     ZYTIGA / abiraterone acetate
 
 
 
 
 
 
 
 
 
     US
 
 
383

 
893

 
(57.1
)
(57.1
)
—

     Intl
 
 
994

 
861

 
15.4

22.6

(7.2
)
     WW
 
 
1,377

 
1,754

 
(21.5
)
(18.0
)
(3.5
)
     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 
154

 
86

 
77.7

77.7

—

     Intl
 
 
179

 
184

 
(2.5
)
5.3

(7.8
)
     WW
 
 
333

 
270

 
23.2

28.6

(5.4
)
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
SIX MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
PULMONARY HYPERTENSION
 
 
 
 
 
 
US
 
$
869

 
790

 
10.0
 %
10.0
 %
—
 %
Intl
 
 
477

 
460

 
3.7

10.7

(7.0
)
WW
 
 
1,346

 
1,250

 
7.7

10.2

(2.5
)
     OPSUMIT
 
 
 
 
 
 
 
 
 
     US
 
 
375

 
329

 
14.2

14.2

—

     Intl
 
 
279

 
253

 
10.3

18.0

(7.7
)
     WW
 
 
654

 
582

 
12.5

15.8

(3.3
)
     TRACLEER
 
 
 
 
 
 
 
 
 
     US
 
 
102

 
139

 
(26.3
)
(26.3
)
—

     Intl
 
 
118

 
144

 
(18.7
)
(14.6
)
(4.1
)
     WW
 
 
220

 
283

 
(22.4
)
(20.3
)
(2.1
)
     UPTRAVI
 
 
 
 
 
 
 
 
 
     US
 
 
351

 
279

 
25.9

25.9

—

     Intl
 
 
50

 
32

 
53.1

63.0

(9.9
)
     WW
 
 
401

 
311

 
28.7

29.7

(1.0
)
     OTHER
 
 
 
 
 
 
 
     US
 
 
41

 
43

 
(8.4
)
(8.4
)
—

     Intl
 
 
31

 
31

 
4.1

15.1

(11.0
)
     WW
 
 
72

 
74

 
(3.4
)
1.0

(4.4
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
SIX MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
CARDIOVASCULAR / METABOLISM / OTHER
 
 
 
 
 
 
US
 
$
1,849

 
2,204

 
(16.1
)%
(16.1
)%
—
 %
Intl
 
 
771

 
831

 
(7.2
)
(1.5
)
(5.7
)
WW
 
 
2,620

 
3,035

 
(13.7
)
(12.1
)
(1.6
)
     XARELTO
 
 
 
 
 
 
 
 
 
     US
 
 
1,091

 
1,257

 
(13.2
)
(13.2
)
—

     Intl
 
 
—

 
—

 
—

—

—

     WW
 
 
1,091

 
1,257

 
(13.2
)
(13.2
)
—

     INVOKANA / INVOKAMET
 
 
 
 
 
 
 
 
 
     US
 
 
286

 
373

 
(23.2
)
(23.2
)
—

     Intl
 
 
92

 
90

 
2.6

8.9

(6.3
)
     WW
 
 
379

 
463

 
(18.2
)
(16.9
)
(1.3
)
     PROCRIT / EPREX
 
 
 
 
 
 
 
 
 
     US
 
 
261

 
345

 
(24.3
)
(24.3
)
—

     Intl
 
 
148

 
167

 
(11.7
)
(7.3
)
(4.4
)
     WW
 
 
409

 
512

 
(20.2
)
(18.7
)
(1.5
)
     OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
211

 
229

 
(8.2
)
(8.2
)
—

     Intl
 
 
531

 
574

 
(7.5
)
(1.4
)
(6.1
)
     WW
 
 
742

 
803

 
(7.7
)
(3.4
)
(4.3
)
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
US
 
 
11,365

 
11,253

 
1.0

1.0

—

Intl
 
 
9,408

 
8,945

 
5.2

12.5

(7.3
)
WW
 
$
20,773

 
20,198

 
2.8
 %
6.1
 %
(3.3
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
SIX MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (5)
 
 
 
 
 
 
 
 
 
 
 
 
 
DIABETES CARE (5)
 
 
 
 
 
 
US
 
$
—

 
246

 
*%

*%

—
 %
Intl
 
 
—

 
448

 
*

*

*

WW
 
 
—

 
694

 
*

*

*

 
 
 
 
 
 
 
 
 
 
INTERVENTIONAL SOLUTIONS
 
 
 
 
 
 
 
 
 
US
 
 
709

 
627

 
13.2

13.2

—

Intl
 
 
774

 
680

 
13.7

20.0

(6.3
)
WW
 
 
1,482

 
1,307

 
13.4

16.7

(3.3
)
 
 
 
 
 
 
 
 
 
 
ORTHOPAEDICS
 
 
 
 
 
 
 
 
 
US
 
 
2,649

 
2,639

 
0.4

0.4

—

Intl
 
 
1,779

 
1,873

 
(5.0
)
1.1

(6.1
)
WW
 
 
4,428

 
4,512

 
(1.9
)
0.7

(2.6
)
 
 
 
 
 
 
 
 
 
 
     HIPS
 
 
 
 
 
 
 
 
 
     US
 
 
429

 
420

 
2.1

2.1

—

     Intl
 
 
295

 
303

 
(2.3
)
4.2

(6.5
)
     WW
 
 
725

 
723

 
0.3

3.0

(2.7
)
 
 
 
 
 
 
 
 
 
 
     KNEES
 
 
 
 
     US
 
 
441

 
457

 
(3.5
)
(3.5
)
—

     Intl
 
 
299

 
312

 
(4.0
)
1.9

(5.9
)
     WW
 
 
741

 
769

 
(3.7
)
(1.3
)
(2.4
)
 
 
 
 
 
 
 
 
 
 
     TRAUMA
 
 
 
 
 
 
 
 
 
     US
 
 
824

 
801

 
2.9

2.9

—

     Intl
 
 
533

 
570

 
(6.5
)
(0.5
)
(6.0
)
     WW
 
 
1,357

 
1,371

 
(1.0
)
1.5

(2.5
)
 
 
 
 
 
 
 
 
 
 
     SPINE & OTHER
 
 
     US
 
 
955

 
961

 
(0.6
)
(0.6
)
—

     Intl
 
 
651

 
688

 
(5.4
)
0.6

(6.0
)
     WW
 
 
1,606

 
1,649

 
(2.6
)
(0.1
)
(2.5
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 


Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
SIX MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (5) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
SURGERY
 
 
 
 
 
 
US
 
$
1,927

 
2,015

 
(4.4
)%
(4.4
)%
—
 %
Intl
 
 
2,821

 
2,923

 
(3.5
)
3.0

(6.5
)
WW
 
 
4,748

 
4,938

 
(3.9
)
0.0

(3.9
)
 
 
 
 
 
 
 
 
 
 
     ADVANCED
 
 
 
 
 
 
 
 
 
     US
 
 
800

 
795

 
0.6

0.6

—

     Intl
 
 
1,209

 
1,176

 
2.8

9.5

(6.7
)
     WW
 
 
2,009

 
1,971

 
1.9

5.9

(4.0
)
 
 
 
 
 
 
 
 
 
 
     GENERAL
 
 
 
 
 
 
 
 
 
     US
 
 
868

 
859

 
1.0

1.0

—

     Intl
 
 
1,339

 
1,437

 
(6.8
)
(0.4
)
(6.4
)
     WW
 
 
2,208

 
2,296

 
(3.9
)
0.1

(4.0
)
 
 
 
 
 
 
 
 
 
 
     SPECIALTY
 
 
 
 
 
 
 
 
 
     US
 
 
259

 
361

 
(28.3
)
(28.3
)
—

     Intl
 
 
273

 
310

 
(12.1
)
(5.4
)
(6.7
)
     WW
 
 
531

 
671

 
(20.8
)
(17.8
)
(3.0
)
 
 
 
 
 
 
 
 
 
 
VISION
 
 
 
 
US
 
 
907

 
899

 
1.0

1.0

—

Intl
 
 
1,383

 
1,389

 
(0.5
)
4.7

(5.2
)
WW
 
 
2,290

 
2,288

 
0.1

3.2

(3.1
)
 
 
 
 
 
 
 
 
 
 
     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
654

 
629

 
4.0

4.0

—

     Intl
 
 
1,011

 
1,022

 
(1.0
)
4.4

(5.4
)
     WW
 
 
1,666

 
1,651

 
0.9

4.2

(3.3
)
     SURGICAL
 
 
 
 
 
 
 
 
 
     US
 
 
253

 
270

 
(6.1
)
(6.1
)
—

     Intl
 
 
371

 
367

 
1.0

5.5

(4.5
)
     WW
 
 
624

 
637

 
(2.0
)
0.6

(2.6
)
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
US
 
 
6,192

 
6,426

 
(3.6
)
(3.6
)
—

Intl
 
 
6,756

 
7,313

 
(7.6
)
(1.6
)
(6.0
)
WW
 
$
12,948

 
13,739

 
(5.7
)%
(2.6
)%
(3.1
)%
 
 
 
 
 
 
 
 
 
 
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
 
 
 
 
 
 
 
 
 
 
* Percentage greater than 100% or not meaningful
 
 
 
 
(1) Operational growth excludes the effect of translational currency
 
 
(2) Unaudited
 
 
 
 
 
 
 
 
 
(3) Reported as U.S. sales
 
 
 
 
 
 
 
 
 
(4) Prior year amounts have been reclassified to conform to current year product disclosure
(5) Reflects LifeScan divestiture October 2, 2018